Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$13.57 USD

13.57
6,458,473

-0.05 (-0.37%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $13.56 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at an 88.6% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Biohaven Ltd. (BHVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 127.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Company News for Mar 4, 2025

by Zacks Equity Research

Companies In The News Are: CRC, TGTX, NOMD, BHVN.

Zacks Equity Research

Company News for Jan 2, 2025

by Zacks Equity Research

Companies In The News Are: X, BHVN, SGMO, PFE, BLDR.

Zacks Equity Research

SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal

by Zacks Equity Research

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

Zacks Equity Research

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

by Zacks Equity Research

Biohaven and Zevra are in the spotlight following positive updates on key candidates.

Zacks Equity Research

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

by Zacks Equity Research

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

Zacks Equity Research

Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

Zacks Equity Research

Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround

by Zacks Equity Research

Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.